Patricia J Giardina
Overview
Explore the profile of Patricia J Giardina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapin J, Cohen A, Neufeld E, Vichinsky E, Giardina P, Boudreaux J, et al.
Br J Haematol
. 2021 Nov;
196(2):380-389.
PMID: 34775608
Thalassaemia is caused by genetic globin defects leading to anaemia, transfusion-dependence and comorbidities. Reduced survival and systemic organ disease affect transfusion-dependent thalassaemia major and thalassaemia intermedia. Recent improvements in clinical...
2.
Vichinsky E, Cohen A, Thompson A, Giardina P, Lal A, Paley C, et al.
Pediatr Blood Cancer
. 2018 Apr;
65(7):e27067.
PMID: 29637688
Background: Nontransfusion-dependent thalassemia (NTDT) refers to a diverse group of thalassemia mutations and clinical phenotypes that do not require chronic transfusions. It is increasingly prevalent in the United States. Procedure:...
3.
Taher A, Saliba A, Kuo K, Giardina P, Cohen A, Neufeld E, et al.
Am J Hematol
. 2017 Sep;
92(12):1356-1361.
PMID: 28940308
Our phase I, open-label, multi-center, dose-escalation study evaluated the pharmacokinetics (PK) of SP-420, a tridentate oral iron chelating agent of the desferrithiocin class, in patients with transfusion dependent β-thalassemia. SP-420...
4.
Spitzer B, Giardina P, OReilly R, Boulad F
Pediatr Blood Cancer
. 2015 Mar;
62(7):1303-4.
PMID: 25810133
No abstract available.
5.
Vichinsky E, Neumayr L, Trimble S, Giardina P, Cohen A, Coates T, et al.
Transfusion
. 2013 Jul;
54(4):972-81.
PMID: 23889533
Background: Transfusions are the primary therapy for thalassemia but have significant cumulative risks. In 2004, the Centers for Disease Control and Prevention (CDC) established a national blood safety monitoring program...
6.
Thompson A, Kim H, Singer S, Vichinsky E, Eile J, Yamashita R, et al.
Am J Hematol
. 2013 Jun;
88(9):771-3.
PMID: 23757266
Improved survival in thalassemia has refocused attention on quality of life, including family planning. Understanding the issues associated with infertility and adverse pregnancy outcomes may impact clinical care of patients...
7.
Ambati S, Randolph R, Mennitt K, Kleinert D, Weinsaft J, Giardina P
Am J Hematol
. 2013 May;
88(8):652-6.
PMID: 23640778
Cardiovascular magnetic resonance (CMR) and hepatic magnetic resonance imaging (MRI) have become reliable noninvasive tools to monitor iron excess in thalassemia major (TM) patients. However, long-term studies are lacking. We...
8.
Goldberg S, Giardina P, Chirnomas D, Esposito J, Paley C, Vichinsky E
Pediatr Blood Cancer
. 2013 May;
60(9):1507-12.
PMID: 23637051
Background: Deferasirox is a once-daily, oral iron chelator that was developed out of a need for a long-acting, conveniently-administered chelator for patients with transfusional hemosiderosis. The approved mode of administration...
9.
Wiseman D, May A, Jolles S, Connor P, Powell C, Heeney M, et al.
Blood
. 2013 Apr;
122(1):112-23.
PMID: 23553769
Congenital sideroblastic anemias (CSAs) are a heterogeneous group of inherited disorders identified by pathological erythroid precursors with perinuclear mitochondrial iron deposition in bone marrow. An international collaborative group of physicians...
10.
Ramos P, Casu C, Gardenghi S, Breda L, Crielaard B, Guy E, et al.
Nat Med
. 2013 Mar;
19(4):437-45.
PMID: 23502961
Regulation of erythropoiesis is achieved by the integration of distinct signals. Among them, macrophages are emerging as erythropoietin-complementary regulators of erythroid development, particularly under stress conditions. We investigated the contribution...